Features
Santé Cannabis champions medical research for cannabis patients six years post-legalization
In a bid to keep medical cannabis needs front and center, Santé Cannabis is launching a three-year study with 3,000 patients to explore the efficacy of emerging cannabis treatments
November 4, 2024 By David Silverberg
Photo: Adobe Stock Santé Cannabis doesn’t want Canada to forget about the medical needs of cannabis users six years after legalization, and they are stepping up to do something about it.
The Quebec cannabis medical clinic announced they’re launching a three-year observational study into emerging cannabis treatments, with the goal of enlisting 3,000 patients.
The voluntary study asks Santé clients, who receive treatment plans through the Montreal-based clinical service, to complete a questionnaire on the type of cannabis and ingestion method they are using, how effective it is in managing their medical conditions, if they found the cost to be reasonable, quality of life assessments, and much more.
“We’ve seen how there are new formats, like suppositories, and there hasn’t been on a lot of research into these specific product formats,” says Erin Prosk, president and CEO of Santé Cannabis, in an interview. “The goal of this study is to improve patient outcomes and to reinvest into research to understand which products are most therapeutic to our patients.”
To that end, the clinic has partnered with LPs Aurora and Tilray in order for the producers to receive anonymized data on the products they offer and better refine them in the future, Prosk adds.
She explains that when a patient agrees to take part in the study, they’ll answer a questionnaire four times within a year, aligning with their quarterly visits to Santé’s clinics (either online or offline).
Prosk says these kinds of studies aren’t just a nice-to-have but a priority. “Without research like this, patients end up experimenting with trial-and-error and they become disconnected from the medical and health care community.”
Print this page